



Great debates in Hematology

Saturday, 8th June 2024, 9.00 am - 5.30 pm

Venue: Conference Hall, 4th floor, Old Building,
P D Hinduja Hospital, Mahim, Mumbai

Each debate will be for 25 minutes (10 minutes each for the speaker and 5 minutes for rebuttal and discussion)

Time	Subject	Speaker
9.00 am - 9.30 am	Fellowship (Breakfast)	
9.30 am - 9.50 am	Quiz for UG, PG & DM students	Quiz Master Dr. M. B. Agarwal
9.50 am - 10.00 am	Welcome address	Dr. Shanaz Khodajji
Debate 1		
10.00 am - 10.25 am	Chair: Dr. Varsha Vadera, Dr. V. P. Antia, Dr. Girish Rajadhyaksha	
	Iron therapy should preferably be oral. vs Iron therapy should preferably be parenteral. (This debate is supported by Zydus)	Dr. Ruchira Misra vs Dr. Swati Kanakia
Debate 2		
10.25 am - 10.50 am	Chair: Dr. Shubhangi Agale, Dr. Vrinda Kulkarni, Dr. Sujata Sharma	
	Splenectomy is obsolete in the treatment of ITP. vs Splenectomy remains an effective modality of treatment of ITP. (This debate is supported by Intas)	Dr. Asha Shah vs Dr. Farah Jijina
Debate 3		
10.50 am - 11.15 am	Chair: Dr. Samir Shah, Dr. Anjana Sainani, Dr. Prathamesh Kulkarni	
	In the treatment of DLBCL, Polatuzumab Vedotin based treatment is a dramatic shift. vs In the treatment of DLBCL, Polatuzumab Vedotin based treatment is just a small step forward. (This debate is supported by Roche)	Dr. Subhaprakash Sanyal vs Dr. Aditi Shah Kaskar
Debate 4		
11.15 am - 11.40 am	Chair: Dr. Ambreen Pandrowala, Dr. Bipin Kulkarni, Dr. Rucha Patil	
	Non-factor based therapy makes factor based replacement therapy obsolete in the care of hemophilia. vs Even in the era of non-factor based therapy, factor replacement based therapy remains the standard of care for hemophiliacs. (This debate is supported by Novo Nordisk)	Dr. Chandrakala S vs Dr. Ritika Khurana

Time	Subject	Speaker
Debate 5		
11.40 am - 12.05 pm	<p>Chair: Dr. Amar Dasgupta, Dr. Namita Padwal, Dr. Govind Kendre, Dr. Omkar Khandkar</p> <p>DOACs replace warfarin as the oral anticoagulant of choice. vs Warfarin, the old horse, still remains the oral anticoagulant of choice.</p> <p>(This debate is supported by Intas Aquilla)</p>	<p>Dr. Rajesh Patil vs Dr. Shilpa Gupta</p>
Debate 6		
12.05 pm - 12.30 pm	<p>Chair: Dr. Manisha Madkaikar, Dr. Shweta Bansal, Dr. Adwaita Gore, Dr. Kriti Hegde</p> <p>ATG + Cyclosporin + Eltrombopag is the standard of care for most acquired aplastic anemia. vs Stem cell therapy is the standard of care for most acquired aplastic anemia.</p> <p>(This debate is supported by Lucien)</p>	<p>Dr. Shrinath Kshirsagar vs Dr. Priti Mehta</p>
Lecture		
12.30 pm - 1.00 pm	<p>Chair: TBD</p> <p>Shingles prevention: Time is now_A Hemato-Oncology Perspective</p> <p>(This lecture is supported by GSK)</p>	<p>Dr. Umang Agrawal</p>
1.00 pm - 1.45 pm	Lunch	
Debate 7		
1.45 pm - 2.15 pm	<p>Chair: Dr. Rohit Pai, Dr. Bharat Bhosale</p> <p>Brentuximab Vedotin (BV) based treatment is the best for Relapsed/Refractory Hodgkin Lymphoma vs Checkpoint inhibitors (Nivo / Pembro) based therapy replaces BV in the treatment of R/R HL</p>	<p>Dr. Subhaprakash Sanyal vs Dr. Rajesh Patil</p>
Debate 8		
2.15 pm - 2.45 pm	<p>Chair: Dr. Kunal Sehgal, Dr. Syed Hasan, Dr. Vipin Khandelwal</p> <p>Even a young-fit AML should receive HMA + Ven as a bridge to transplant. vs 7+3 or similar chemo based protocol is necessary for young-fit AML patients needing transplant.</p> <p>(This debate is supported by Adley & Concord)</p>	<p>Dr. Punit Jain vs Dr. Sumeet Mirgh</p>

Time	Subject	Speaker
Debate 9		
2.45 pm - 3.15 pm	<p>Chair: Dr. Ganapathi Bhatt, Dr. Ashish Joshi, Dr Amrit Kaur Kaler</p> <p>For relapsed adult B-cell ALL, Inotuzumab ozogamicin monotherapy is the best bridge to transplant.</p> <p>vs</p> <p>For relapsed adult B-cell ALL, Hyper-C-VAD with or without Blinatumomab is the best bridge to transplant.</p> <p>(This debate is supported by Pfizer)</p>	<p>Dr. Hamza Dalal vs Dr. Lingaraj Nayak</p>
Debate 10		
3.15 pm - 3.45 pm	<p>Chair: Dr. Anand Deshpande, Dr. Mukesh Sanklecha, Dr. Chintan Vyas, Dr. Amit Jain</p> <p>Most sickle cell disease patients deserve a cure by transplant</p> <p>vs</p> <p>Transplant should be sparingly used for patients of sickle cell disease.</p> <p>(This debate is supported by Sun Pharma)</p>	<p>Dr. Santanu Sen vs Dr. Purva Kanvinde</p>
Debate 11		
3.45 pm - 4.15 pm	<p>Chair: Dr. Reetu Jain, Dr. Darshana Rane, Dr. Rizwan Shaikh, Dr. Anbarasan Sekar</p> <p>Daratumumab is necessary for all newly diagnosed myeloma patients.</p> <p>vs</p> <p>VRd without Daratumumab is adequate for most newly diagnosed myeloma patients:</p> <p>(This debate is supported by Janssen)</p>	<p>Dr. Arun VA vs Dr. Bhausasheb Bagal</p>
Debate 12		
4.15 pm - 4.45 pm	<p>Chair: Dr. Bhavna Parikh, Dr. Pratibha Amare Kadam, Dr. Akshay Shah, Dr. Parth Ganatra</p> <p>With the option of CAR-T for relapsed myeloma, autologous stem cell transplant is not needed for treatment of newly diagnosed myeloma.</p> <p>vs</p> <p>Autologous stem cell transplant still remains the standard of care for newly diagnosed myeloma, even with the option of CAR-T for the relapsed situation.</p> <p>(This debate is supported by Dr. Reddy's)</p>	<p>Dr. Gaurav Narula vs Dr. Reetu Jain</p>
Debate 13		
4.45 pm - 5.15 pm	<p>Chair: Dr. Gaurav Narula, Dr. Syed Hasan, Dr. Darshana Rane</p> <p>Ruxolitinib is a game changer for patients of MPN</p> <p>vs</p> <p>Ruxolitinib has added very little to the life of patients with MPN</p> <p>(This debate is supported by Novartis)</p>	<p>Dr. Dipanjan Haldar vs Dr. Hamza Dalal</p>
5.15 pm - 5.30 pm	Prize distribution & concluding remarks	Dr. Vidisha Mahajan